Skip to content
Dx

ICD-10-CM 2027 diagnosis code

C88.31Immunoproliferative small intestinal disease, in remission

✓ Billable / specificCC — complication/comorbidity

C88.31 is a valid, billable ICD-10-CM code for immunoproliferative small intestinal disease, in remission. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Code last changed in FY2025 (effective October 1, 2024). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About C88.31

C88.31 is the ICD-10-CM diagnosis code for immunoproliferative small intestinal disease, in remission. It belongs to category C88 (malignant immunoproliferative diseases and certain other B-cell lymphomas), block C81-C96 (malignant neoplasms of lymphoid, hematopoietic and related tissue) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within C88.3 (immunoproliferative small intestinal disease), C88.31 is specifically for immunoproliferative small intestinal disease, in remission. Related codes cover not having achieved remission (C88.30).

As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.

In MS-DRG v44.0, it is part of the grouping logic for DRG 820 (Lymphoma and Leukemia with Major O.R. Procedures with MCC, relative weight 6.2481), DRG 821 (Lymphoma and Leukemia with Major O.R. Procedures with CC, relative weight 2.2023), DRG 822 (Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC, relative weight 1.1272), DRG 823 (Lymphoma and Non-Acute Leukemia with Other Procedures with MCC, relative weight 4.6059), DRG 824 (Lymphoma and Non-Acute Leukemia with Other Procedures with CC, relative weight 2.2515), DRG 825 (Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC, relative weight 1.2995) and 3 more, in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It was added in FY2025, effective October 1, 2024.

Notes that apply from higher levels

Instructions written at a parent level also apply to C88.31.

› From C88 Malignant immunoproliferative diseases and certain other B-cell lymphomas
Excludes1
  • B-cell lymphoma, unspecified (C85.1-)
  • personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues (Z85.79)

Broader instructions also apply from C81-C96 Malignant neoplasms of lymphoid, hematopoietic and related tissue and Chapter 2: Neoplasms.

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2025 (effective 10/1/2024): Added
  • No changes since FY2025.

Common questions about C88.31

Is C88.31 billable?

Yes. C88.31 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can C88.31 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict C88.31 as a principal diagnosis.

Is C88.31 a CC or MCC?

C88.31 is a CC (complication or comorbidity) under MS-DRG v44.0, unless excluded by the principal diagnosis.

What DRG does C88.31 group to?

C88.31 is used in the MS-DRG v44.0 logic for MS-DRG 820 (Lymphoma and Leukemia with Major O.R. Procedures with MCC), MS-DRG 821 (Lymphoma and Leukemia with Major O.R. Procedures with CC), MS-DRG 822 (Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC), MS-DRG 823 (Lymphoma and Non-Acute Leukemia with Other Procedures with MCC), MS-DRG 824 (Lymphoma and Non-Acute Leukemia with Other Procedures with CC), MS-DRG 825 (Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC) and 3 more. Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.